April 13, 2010 (FinancialWire) — RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, said that it has entered into a research collaboration with Mirna Therapeutics to determine the utility of combining RXi’s proprietary rxRNA technology with Mirna’s microRNA mimics as potential therapeutics in oncology.

According to RXi, the parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

Financial terms of the collaboration were not disclosed.

microRNAs are naturally occurring small RNA molecules involved in numerous biological processes. Misregulation of microRNAs has been recently demonstrated to be associated with various human disorders, including cancer, cardiovascular, inflammation and metabolic diseases, according to RXi.

Massachusetts-based RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases.

The firm has a therapeutic platform that includes both novel RNAi compounds and advanced delivery methods that can potentially be applied for local and systemic applications, against targets that may be undruggable by other modalities.

Texas-based Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA therapeutics. The company has a body of pending intellectual property around miRNAs developed by its own scientists as well as in-licensed from other institutions.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [nwdlsldw] [prtnrshpsphs]